A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation

Spebrutinib (SBT) is a Bruton's tyrosine kinase inhibitor. SBT is currently in phase II and phase I clinical trials for the management of rheumatoid arthritis and chronic lymphocytic leukaemia, respectively. We developed and validated a liquid chromatography tandem mass spectrometry analytical...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelhameed, Ali S., Attwa, Mohamed W., Al-Shaklia, Nasser S., Kadi, Adnan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society 2019
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599791/
https://www.ncbi.nlm.nih.gov/pubmed/31312501
http://dx.doi.org/10.1098/rsos.190434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599791/
https://www.ncbi.nlm.nih.gov/pubmed/31312501
http://dx.doi.org/10.1098/rsos.190434

Ejemplares similares